Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23:1761-1767
Published online before print August 28, 2003, doi: 10.1161/01.ATV.0000092941.77774.3C
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
23/10/1761    most recent
01.ATV.0000092941.77774.3Cv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Friedrich, E. B.
Right arrow Articles by Gerszten, R. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Friedrich, E. B.
Right arrow Articles by Gerszten, R. E.
Related Collections
Right arrow Other Ethics and Policy
Right arrow Coagulation inhibitors
Right arrow Coagulation and fibronolysis
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23:1761.)
© 2003 American Heart Association, Inc.


Vascular Biology

Mechanisms of Leukotriene B4–Triggered Monocyte Adhesion

Erik B. Friedrich; Andrew M. Tager; Emerson Liu; Annika Pettersson; Christer Owman; Lance Munn; Andrew D. Luster; Robert E. Gerszten

From the Center for Immunology and Inflammatory Diseases (E.B.F., A.M.T., E.L., A.D.L., R.E.G.), the Cardiology Division (R.E.G.), and the Department of Radiation Oncology (L.M.), Massachusetts General Hospital, Charlestown, Mass; and the Wallenberg Neuroscience Center (A.P., C.O.), Lund University, Lund, Sweden.

Correspondence to Robert E. Gerszten, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital East-8307, 149 13th St, Charlestown, MA 02129. E-mail rgerszten{at}partners.org

Objective— Leukotriene B4 (LTB4) has been implicated in the trafficking of monocytes to inflammatory pathologic conditions, such as transplant rejection and atherosclerosis. The aim of this study was to determine the mechanisms by which LTB4 contributes to monocyte capture from the circulation.

Methods and Results— In in vitro and in vivo vascular models, the lipid chemoattractant LTB4 was an equipotent agonist of monocyte adhesion compared with the chemokine monocyte chemoattractant protein-1 (MCP-1). Adenoviral gene transfer of specific endothelial adhesion molecules and blocking monoclonal antibody studies demonstrated that LTB4 triggers both ß1- and ß2-integrin–dependent adhesion. Flow cytometry studies suggested that changes in integrin avidity or affinity, rather than alterations of integrin surface expression, were responsible for the chemoattractant-triggered arrest. Surprisingly, in contrast to the peptide chemokine MCP-1, LTB4 did not activate the phosphoinositide 3-kinase pathway, which is a functionally critical step in chemokine-triggered effector functions.

Conclusions— LTB4 is a potent trigger of monocyte adhesion under flow yet mediates its effects via pathways that appear to differ from peptide chemoattractants. A better understanding of the mechanisms of LTB4-induced monocyte trafficking might shed insight into disease pathogenesis and pinpoint critical steps for therapeutic intervention for multiple human inflammatory pathologic conditions.


Key Words: Please supply key words




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
N. L. Rao, P. J. Dunford, X. Xue, X. Jiang, K. A. Lundeen, F. Coles, J. P. Riley, K. N. Williams, C. A. Grice, J. P. Edwards, et al.
Anti-Inflammatory Activity of a Potent, Selective Leukotriene A4 Hydrolase Inhibitor in Comparison with the 5-Lipoxygenase Inhibitor Zileuton
J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 1154 - 1160.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
M. Back, A. Sultan, O. Ovchinnikova, and G. K. Hansson
5-Lipoxygenase-Activating Protein: A Potential Link Between Innate and Adaptive Immunity in Atherosclerosis and Adipose Tissue Inflammation
Circ. Res., April 13, 2007; 100(7): 946 - 949.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
C. Vidal, A. Gomez-Hernandez, E. Sanchez-Galan, A. Gonzalez, L. Ortega, J. A. Gomez-Gerique, J. Tunon, and J. Egido
Licofelone, a Balanced Inhibitor of Cyclooxygenase and 5-Lipoxygenase, Reduces Inflammation in a Rabbit Model of Atherosclerosis
J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 108 - 116.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
M. Back, D.-x. Bu, R. Branstrom, Y. Sheikine, Z.-Q. Yan, and G. K. Hansson
Leukotriene B4 signaling through NF-{kappa}B-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia
PNAS, November 29, 2005; 102(48): 17501 - 17506.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
A. Pettersson, A. Sabirsh, J. Bristulf, K. Kidd-Ljunggren, B. Ljungberg, C. Owman, and U. Karlsson
Pro- and anti-inflammatory substances modulate expression of the leukotriene B4 receptor, BLT1, in human monocytes
J. Leukoc. Biol., June 1, 2005; 77(6): 1018 - 1025.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Mehrabian and H. Allayee
Vascular Cross-Talk: A Conversation
Arterioscler. Thromb. Vasc. Biol., October 1, 2004; 24(10): 1748 - 1749.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
L. Huang, A. Zhao, F. Wong, J. M. Ayala, M. Struthers, F. Ujjainwalla, S. D. Wright, M. S. Springer, J. Evans, and J. Cui
Leukotriene B4 Strongly Increases Monocyte Chemoattractant Protein-1 in Human Monocytes
Arterioscler. Thromb. Vasc. Biol., October 1, 2004; 24(10): 1783 - 1788.
[Abstract] [Full Text] [PDF]